Dynavax to Present at Upcoming June 2024 Investor Conferences

2024-05-28

疫苗上市批准

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at . About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit and follow Dynavax on LinkedIn and Twitter. For Investors/Media: Paul Cox pcox@dynavax.com 510-665-0499 Nicole Arndt narndt@dynavax.com, 510-665-7264 View original content to download multimedia: SOURCE Dynavax Technologies Company Codes: NASDAQ-SMALL:DVAX

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Dynavax GmbH